Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria I Harrell

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Molecular Microbiology|April 16, 2003
Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosisHeui-Dong Park, Kristi M Guinn, Maria I Harrell, et al.
Gynecologic Oncology|August 31, 2016
Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinomaChristopher B Morse, Barbara M Norquist, Maria I Harrell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2016
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissuesJeffrey D Krimmel, Michael W Schmitt, Maria I Harrell, et al.
The Journal of Clinical Investigation|July 26, 2016
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistanceYifan Wang, John J Krais, Andrea J Bernhardy, et al.
Gynecologic Oncology|December 25, 2012
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testingBarbara M Norquist, Kathryn P Pennington, Kathy J Agnew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative NeoplasmsKeith W Pratz, Brian D Koh, Anand G Patel, et al.
JAMA Oncology|February 6, 2016
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian CarcinomaElizabeth M Swisher, Maria I Harrell, Barbara M Norquist, et al.
Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.
The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2013
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasKathryn P Pennington, Tom Walsh, Maria I Harrell, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Molecular Microbiology|April 16, 2003
Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosisHeui-Dong Park, Kristi M Guinn, Maria I Harrell, et al.
Gynecologic Oncology|August 31, 2016
Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinomaChristopher B Morse, Barbara M Norquist, Maria I Harrell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2016
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissuesJeffrey D Krimmel, Michael W Schmitt, Maria I Harrell, et al.
The Journal of Clinical Investigation|July 26, 2016
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistanceYifan Wang, John J Krais, Andrea J Bernhardy, et al.
Gynecologic Oncology|December 25, 2012
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testingBarbara M Norquist, Kathryn P Pennington, Kathy J Agnew, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative NeoplasmsKeith W Pratz, Brian D Koh, Anand G Patel, et al.
JAMA Oncology|February 6, 2016
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian CarcinomaElizabeth M Swisher, Maria I Harrell, Barbara M Norquist, et al.
Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.
The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2013
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasKathryn P Pennington, Tom Walsh, Maria I Harrell, et al.
Pageof 4